MedImmune and Joslin Diabetes Center announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders.
MedImmune and Joslin researchers will work collaboratively on research projects to identify new drug candidates.
Three initial projects have been identified, focusing on several key areas including protecting and regenerating the insulin producing beta cells, increasing the caloric utilization of fat depots (“beiging” white fat or expanding brown fat), and replicating the beneficial effects of bariatric surgery pharmacologically.
|Searching for more deal information? Current Partnering offers the following options:|
The collaboration is structured with the potential for more projects to be added as new compelling science is identified.
MedImmune will provide research funding to Joslin and bring drug development expertise and capabilities to complement Joslin’s early metabolic disease research competencies and clinical care infrastructure.
MedImmune has the option to license development and commercial rights to projects emerging from the collaboration.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies